The company said it will use the funds to continue developing new companion diagnostics and expand commercialization of its VeriStrat and GeneStrat products
The company last year launched a PCR-based assay for identifying mutations in lung cancer patients and plans to release an NGS-based test later this year.
In a study looking at a total of 149 subjects with advanced unresectable melanoma, the test proved useful for distinguishing between good and poor responders.
The Colorado-based cancer diagnostics firm said in an SEC document that it seeks to raise up to $20 million.
The effort will use Biognosys' HRM method to complement its MALDI-TOF approach to biomarker work, a company official said.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
The $11 million is in addition to $27 million that the company raised previously in a Series E financing, bringing the total proceeds to $38 million.
The company has received similar coverage decisions from other payors in recent months.
The decision means that UnitedHealthcare's members will have access to Biodesix's test for advanced NSCLC as a covered benefit.
The proteomics test to guide treatment of non-small cell lung cancer will be covered for 3.4 million patients in Maryland, DC, and Virginia.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.